Fabian Trillsch

Department of Obstetrics and Gynecology, University Hospital, Ludwig-Maximilian-University (LMU) Munich

Affiliated withUniversity Hospital, Ludwig-Maximilian-University (LMU) Munich German Cancer Consortium (DKTK), Partner site Munich (LMU), a partnership between the German Cancer Research Center (DKFZ) and the University Hospital of LMU Munich

Research Area

Cancer Research

Biography

Fabian Trillsch has not added Biography.
If you are Fabian Trillsch and would like to personalize this page please email our Author Liaison for assistance.

JoVE Journal Publications

ArticleTotal : 1	Year
Publication title Cited by 5	2024

Other Publications

Article	Year
The genetic landscape of 87 ovarian germ cell tumors. Gynecologic oncology\| PubMed ID: 30170975	2018
Interaction of ERα and NRF2 Impacts Survival in Ovarian Cancer Patients. International journal of molecular sciences\| PubMed ID: 30597961	2018
Potential Interplay of the Gatipotuzumab Epitope TA-MUC1 and Estrogen Receptors in Ovarian Cancer. International journal of molecular sciences\| PubMed ID: 30642093	2019
Correlation of the Aryl Hydrocarbon Receptor with FSHR in Ovarian Cancer Patients. International journal of molecular sciences\| PubMed ID: 31212758	2019
M2 Macrophages Infiltrating Epithelial Ovarian Cancer Express MDR1: A Feature That May Account for the Poor Prognosis. Cells\| PubMed ID: 32429133	2020
Cytoplasmic VDR expression as an independent risk factor for ovarian cancer. Histochemistry and cell biology\| PubMed ID: 32572587	2020
Potential of platinum-resensitization by Wnt signaling modulators as treatment approach for epithelial ovarian cancer. Journal of cancer research and clinical oncology\| PubMed ID: 32681294	2020
β-arrestin 2 Is a Prognostic Factor for Survival of Ovarian Cancer Patients Upregulating Cell Proliferation. Frontiers in endocrinology\| PubMed ID: 33042017	2020
Nuclear Enolase-1/ MBP-1 expression and its association with the Wnt signaling in epithelial ovarian cancer. Translational oncology\| PubMed ID: 33069100	2021
Primary platinum resistance and its prognostic impact in patients with recurrent ovarian cancer: an analysis of three prospective trials from the NOGGO study group. Journal of gynecologic oncology\| PubMed ID: 33825355	2021
Breast adipose tissue macrophages (BATMs) have a stronger correlation with breast cancer survival than breast tumor stroma macrophages (BTSMs). Breast cancer research : BCR\| PubMed ID: 33849622	2021
Platelet-Activating Factor Acetylhydrolase Expression in BRCA1 Mutant Ovarian Cancer as a Protective Factor and Potential Negative Regulator of the Wnt Signaling Pathway. Biomedicines\| PubMed ID: 34206491	2021
Diagnostic workup for endometrioid borderline ovarian tumors (eBOT) requires histopathological evaluation of the uterus. Journal of ovarian research\| PubMed ID: 34233728	2021
Functional Analysis of Non-Genetic Resistance to Platinum in Epithelial Ovarian Cancer Reveals a Role for the MBD3-NuRD Complex in Resistance Development. Cancers\| PubMed ID: 34359703	2021
The Platelet-Activating Factor Receptor's Association with the Outcome of Ovarian Cancer Patients and Its Experimental Inhibition by Rupatadine. Cells\| PubMed ID: 34571986	2021
Efficacy and safety of olaparib according to age in BRCA1/2-mutated patients with recurrent platinum-sensitive ovarian cancer: Analysis of the phase III SOLO2/ENGOT-Ov21 study. Gynecologic oncology\| PubMed ID: 35115180	2022
PLA2G7/PAF-AH as Potential Negative Regulator of the Wnt Signaling Pathway Mediates Protective Effects in BRCA1 Mutant Breast Cancer. International journal of molecular sciences\| PubMed ID: 36614323	2023
Nuclear receptor co-repressor NCOR2 and its relation to GPER with prognostic impact in ovarian cancer. Journal of cancer research and clinical oncology\| PubMed ID: 37131060	2023
KLF11 is an independent negative prognostic factor for breast cancer from a cohort study and induces proliferation and inhibits apoptosis in vitro. Breast cancer (Tokyo, Japan)\| PubMed ID: 37199905	2023